Kissei Pharmaceutical

Update in progress

4547.T (Tokyo)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Kissei Pharmaceutical Co., Ltd. develops, manufactures, and sells medicines mainly in Japan. Its portfolio includes Calogra for ulcerative colitis; Tabneos for microscopic polyangiitis; Minirin Melt OD; Corsuba IV syringe for chronic ITP; Beova for overactive bladder; and Darbepoetin Alfa BS for renal anemia. Its pipeline includes CG0070 for non-muscle-invasive bladder cancer, Linzagolix for fibroids and endometriosis, KDT-3594 for Parkinson’s, KSP-0243 for ulcerative colitis, and Difelikefalin for uremic pruritus. Founded 1946, based in Matsumoto.

Company score

Sentiment: 0.27; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.23; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.12; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.09; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.18; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive